First Hawaiian Bank Halozyme Therapeutics, Inc. Transaction History

First Hawaiian Bank

$3.01 Billion
Q4 2024

A detailed history of First Hawaiian Bank transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, First Hawaiian Bank holds 57,550 shares of HALO stock, worth $3.21 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

57,550

Previous 36,850 56.17%

Holding current value

$3.21 Million

Previous $2.11 Million 30.5%

% of portfolio

0.09%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 08, 2025	BUY	$42.57 - $61.09 $881,199 - $1.26 Million	20,700 Added 56.17%	57,550 $2.75 Million
Q3 2024 Oct 04, 2024	BUY	$51.3 - $64.42 $1.6 Million - $2.01 Million	31,279 Added 561.46%	36,850 $2.11 Million
Q2 2024 Jul 02, 2024	BUY	$37.81 - $52.4 $20,039 - $27,772	530 Added 10.51%	5,571 $291,000
Q1 2024 Apr 05, 2024	SELL	$33.68 - $41.95 $296,720 - $369,579	-8,810 Reduced 63.61%	5,041 $205,000
Q4 2023 Jan 08, 2024	SELL	$33.32 - $42.1 $75,469 - $95,356	-2,265 Reduced 14.05%	13,851 $511,000
Q3 2023 Oct 10, 2023	SELL	$36.46 - $44.03 $17,500 - $21,134	-480 Reduced 2.89%	16,116 $615,000
Q2 2023 Jul 06, 2023	BUY	$30.28 - $38.74 $1,544 - $1,975	51 Added 0.31%	16,596 $598,000
Q1 2023 Apr 18, 2023	SELL	$32.86 - $55.7 $352,916 - $598,218	-10,740 Reduced 39.36%	16,545 $631,000
Q4 2022 Jan 12, 2023	SELL	$40.06 - $59.44 $187,080 - $277,584	-4,670 Reduced 14.61%	27,285 $1.55 Million
Q3 2022 Oct 05, 2022	BUY	$38.53 - $51.78 $132,928 - $178,641	3,450 Added 12.1%	31,955 $1.26 Million
Q2 2022 Jul 22, 2022	BUY	$37.35 - $48.3 $555,954 - $718,945	14,885 Added 109.29%	28,505 $1.25 Million
Q3 2021 Oct 12, 2021	BUY	$38.47 - $46.42 $523,961 - $632,240	13,620 New	13,620 $554,000

Others Institutions Holding HALO

# of Institutions

539

Shares Held

126M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.77B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Hawaiian Bank, based on Form 13F filings with the SEC.

News

Stay updated on First Hawaiian Bank with notifications on news.

Account

First Hawaiian Bank Halozyme Therapeutics, Inc. Transaction History